Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/22/2025 | $9.00 | Buy | Needham |
| 10/2/2024 | $10.00 | Buy | Guggenheim |
| 7/3/2024 | $7.00 | Overweight | Morgan Stanley |
| 3/14/2024 | $13.00 | Sector Outperform | Scotiabank |
| 12/5/2023 | $3.00 | Overweight | KeyBanc Capital Markets |
| 5/4/2023 | $4.00 | Buy | H.C. Wainwright |
| 8/12/2022 | Overweight → Underweight | JP Morgan | |
| 7/18/2022 | $8.00 | Buy | Truist |
VANCOUVER, Wash. and NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today announced the company will be participating in the following upcoming investor conferences. Jefferies Global Healthcare Conference (New York, NY)Presentation on Thursday, June 5 at 2:00 p.m. Eastern Time / 11:00 a.m. Pacific Time Goldman Sachs 46th Annual Global Healthcare Conference (Miami, FL)Presentation on Monday, June 9 at 8:40 a.m. Eastern Time / 5:40 a.m. Pacific Time TD Cowen 4th Annual Tools/Dx Revolution (Dana Point, CA)June 22-25; Interested parties may contact their TD Cow
Initiated dosing of participants in the first-in-human study of ABS-101 (anti-TL1A antibody), with interim data expected in the second half of 2025 ABS-201 (anti-PRLR) non-human primate (NHP) data demonstrate extended half life and high subcutaneous bioavailability; anticipate Phase 1 initiation in early 2026 Cash, cash equivalents, and short-term investments sufficient to fund operations into the first half of 2027 VANCOUVER, Wash. and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today reported financial and operating results for the qu
Absci becomes clinical stage company with ABS-101, first AI-designed biologic for IBD, beginning Phase 1 trial Preclinical data for ABS-101 demonstrates high potency and potential for quarterly dosing, an improvement in efficacy and convenience over first-generation anti-TL1As Interim data anticipated in the second half of 2025 VANCOUVER, Wash., May 13, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI) a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced that the first healthy volunteers have been dosed in a randomized, placebo-controlled Phase 1 study evaluating ABS-101, an investigational anti-TL1A antibody engineer
Sir Pangalos is a distinguished biopharmaceutical executive who led BioPharmaceuticals R&D at AstraZeneca. In addition to joining Absci's Board, Sir Pangalos will co-chair Absci's Scientific Advisory Board. VANCOUVER, Wash., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a generative AI drug creation company, today announced the appointment of seasoned R&D executive Professor Sir Menelas "Mene" Pangalos to its Board of Directors and as co-chair of Absci's Scientific Advisory Board. Sir Pangalos was the Executive Vice President of BioPharmaceuticals R&D at AstraZeneca. He joins Absci as the company scales its AI-enabled portfolio of partnered and wholly-owned assets. "The rapid e
VANCOUVER, Wash., June 06, 2023 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a generative AI drug creation company, today announced the appointment of Frans van Houten to its Board of Directors. With his exceptional leadership experience and deep industry knowledge in the healthcare and technology industries, van Houten will play a pivotal role in supporting Absci's strategic vision and growth trajectory. Frans van Houten is a highly regarded business executive with a remarkable track record of success. During his tenure as CEO of Royal Philips, van Houten led the company's transformation into a global leader in health technology, overseeing a critical strategic transformation, resulting in a
VANCOUVER, Wash. and NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a generative AI drug creation company, today announced Meta Connectivity VP Dan Rabinovitsj as the newest member of its Board of Directors. With three decades of leadership in scaling technologies, innovating business models and growing companies, Mr. Rabinovitsj will provide strategic insights as Absci continues to scale its unprecedented combination of AI and wet lab capabilities to help create better biologics for patients, faster. "Absci has impressed me with their technology and data, together which have the potential to turn Absci's bold vision into reality: to create therapeutics at a
4 - Absci Corp (0001672688) (Issuer)
SC 13G - Absci Corp (0001672688) (Subject)
SC 13G/A - Absci Corp (0001672688) (Subject)
SC 13D/A - Absci Corp (0001672688) (Subject)
4 - Absci Corp (0001672688) (Issuer)
4 - Absci Corp (0001672688) (Issuer)
4 - Absci Corp (0001672688) (Issuer)
Needham initiated coverage of Absci Corporation with a rating of Buy and set a new price target of $9.00
Guggenheim initiated coverage of Absci Corporation with a rating of Buy and set a new price target of $10.00
Morgan Stanley initiated coverage of Absci Corporation with a rating of Overweight and set a new price target of $7.00
Initiated dosing of participants in the first-in-human study of ABS-101 (anti-TL1A antibody), with interim data expected in the second half of 2025 ABS-201 (anti-PRLR) non-human primate (NHP) data demonstrate extended half life and high subcutaneous bioavailability; anticipate Phase 1 initiation in early 2026 Cash, cash equivalents, and short-term investments sufficient to fund operations into the first half of 2027 VANCOUVER, Wash. and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today reported financial and operating results for the qu
VANCOUVER, Wash. and NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the first quarter 2025 after market close on Tuesday, May 13, 2025. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The webcast will be archived and available for replay after th
Unveiled updates across proprietary pipeline and demonstrated new breakthroughs by AI platform at 2024 R&D Day Entered into collaboration with AMD, including $20 million strategic investment in Absci Achieved 2024 outlook for drug creation partnerships through collaborations with Owkin, Twist Bioscience, Invetx, and Memorial Sloan Kettering Cancer Center Cash, cash equivalents, and short-term investments sufficient to fund operations into the first half of 2027 VANCOUVER, Wash. and NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter and full
SCHEDULE 13G/A - Absci Corp (0001672688) (Subject)
SCHEDULE 13G/A - Absci Corp (0001672688) (Subject)
10-Q - Absci Corp (0001672688) (Filer)